Regeneron’s RGC Signs a Research Collaboration with Colorado Center to Advance the Drug Discovery for Personalized Medicine

 Regeneron’s RGC Signs a Research Collaboration with Colorado Center to Advance the Drug Discovery for Personalized Medicine

Regeneron Reports the US FDA’s Acceptance of Priority Review for REGN-EB3’s BLA to Treat Ebola

Shots:

  • RGC and CCPM to create genomics database of 450,000 DNA samples and corresponding health record from de- identified patients who participated in UCHealth system, and will sequence the DNA samples while producing genomic data which will facilitate translational medical research enabling treatment option for patients
  • The focus of the collbaortaion is to pair the sequence data with de-identified health records for aid in genomic medicine, drug discovery and personalized medicine approaches also leading to expansion of RCG’s genomics initiatives
  • Additionally, the CCPM physicians will also validate any genetic findings from the RGC data enabling the return of clinically-actionable results in their CLIA-certified lab

Click here to read full press release/ article | Ref: Regeneron | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post